CO6190564A2 - Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada - Google Patents

Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada

Info

Publication number
CO6190564A2
CO6190564A2 CO09053830A CO09053830A CO6190564A2 CO 6190564 A2 CO6190564 A2 CO 6190564A2 CO 09053830 A CO09053830 A CO 09053830A CO 09053830 A CO09053830 A CO 09053830A CO 6190564 A2 CO6190564 A2 CO 6190564A2
Authority
CO
Colombia
Prior art keywords
fusion
fgf
receptor
modified soluble
fgf receptor
Prior art date
Application number
CO09053830A
Other languages
English (en)
Spanish (es)
Inventor
Mark Nesbit
Beatrice Cameron
Francis Blanche
Sylvie Sordello
Celine Nicolazzi
Marc Trombe
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39431092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6190564(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centelion filed Critical Centelion
Publication of CO6190564A2 publication Critical patent/CO6190564A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO09053830A 2006-11-28 2009-05-26 Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada CO6190564A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28
EP07290042 2007-01-11

Publications (1)

Publication Number Publication Date
CO6190564A2 true CO6190564A2 (es) 2010-08-19

Family

ID=39431092

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09053830A CO6190564A2 (es) 2006-11-28 2009-05-26 Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada

Country Status (33)

Country Link
US (3) US8119770B2 (OSRAM)
EP (1) EP2092069B2 (OSRAM)
JP (1) JP2010510801A (OSRAM)
KR (1) KR20090102769A (OSRAM)
AR (1) AR063975A1 (OSRAM)
AT (1) ATE509106T1 (OSRAM)
AU (1) AU2007326985C1 (OSRAM)
BR (1) BRPI0719290A2 (OSRAM)
CA (1) CA2668932A1 (OSRAM)
CL (1) CL2007003411A1 (OSRAM)
CO (1) CO6190564A2 (OSRAM)
CR (1) CR10777A (OSRAM)
CY (1) CY1112435T1 (OSRAM)
DK (1) DK2092069T3 (OSRAM)
EA (1) EA018700B1 (OSRAM)
EC (1) ECSP099361A (OSRAM)
GT (1) GT200900137A (OSRAM)
HR (1) HRP20110503T1 (OSRAM)
IL (1) IL198480A0 (OSRAM)
MA (1) MA31143B1 (OSRAM)
MX (1) MX2009005692A (OSRAM)
MY (1) MY145914A (OSRAM)
NI (1) NI200900097A (OSRAM)
NO (1) NO20092414L (OSRAM)
PE (1) PE20081250A1 (OSRAM)
PL (1) PL2092069T3 (OSRAM)
PT (1) PT2092069E (OSRAM)
RS (1) RS51911B (OSRAM)
SI (1) SI2092069T1 (OSRAM)
SV (1) SV2009003272A (OSRAM)
TN (1) TN2009000184A1 (OSRAM)
TW (1) TW200839012A (OSRAM)
WO (1) WO2008065543A2 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504144A (ja) 2003-08-26 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
CA2732449A1 (en) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
ES2600631T3 (es) 2009-11-13 2017-02-10 Five Prime Therapeutics, Inc. Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
AU2015258172B2 (en) * 2010-11-15 2017-01-12 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
NZ610487A (en) * 2010-11-15 2015-03-27 Five Prime Therapeutics Inc Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
UY33833A (es) 2010-12-23 2012-07-31 Sanofi Sa Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
US9938353B2 (en) * 2011-06-24 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US10016484B2 (en) 2011-11-14 2018-07-10 Five Prime Therapeutics, Inc. Methods of treating lung cancer
KR20140137347A (ko) 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
RU2708314C2 (ru) * 2013-03-11 2019-12-05 Джензим Корпорейшн Гипергликозилированные связывающие полипептиды
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
CN105307669A (zh) * 2013-05-23 2016-02-03 戊瑞治疗有限公司 治疗癌症的方法
RS58719B1 (sr) 2013-08-01 2019-06-28 Five Prime Therapeutics Inc Nefukozilisana anti-fgfr2iiib antitela
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
CN108368174B (zh) * 2015-11-23 2023-04-14 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
US11091555B2 (en) 2017-05-16 2021-08-17 Five Prime Therapeutics, Inc. Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
WO2019106592A2 (en) 2017-11-30 2019-06-06 Grifols Diagnostic Solutions Inc. Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1
US12448415B2 (en) * 2018-01-04 2025-10-21 Washington University Compositions and methods for inhibition of alphavirus infection
MA51676A (fr) * 2018-01-26 2021-05-05 Hoffmann La Roche Protéines de fusion il-22 fc et procédés d'utilisation
CA3135032A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288856A (en) 1986-11-20 1994-02-22 Pierre Amiguet Method of isolating acid-stable, biologically active proteins
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5153310A (en) * 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
JP3039802B2 (ja) * 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア 繊維芽細胞成長因子のための受容体
WO1991017183A1 (en) * 1990-04-27 1991-11-14 Takeda Chemical Industries, Ltd. Proteins with fibroblast growth factor receptor activity
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
EP0538404B1 (en) 1990-07-06 2003-06-18 Rhone-Poulenc Rorer International (Holdings) Inc. Fibroblast growth factor receptors
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US6612152B2 (en) * 1999-05-01 2003-09-02 James E. Keaton Lifting, servicing, and diagnosing automobiles
US6656738B1 (en) * 1999-11-17 2003-12-02 Bae Systems Integrated Defense Solutions Inc. Internal heater for preconcentrator
JP2004504016A (ja) * 2000-06-30 2004-02-12 マキシゲン・エイピーエス ペプチド拡張されたグリコシル化ポリペプチド
HU231090B1 (hu) * 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
CA2481837A1 (en) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR ENHANCING ACTIVITY OF BINDING ANTIBODY COMPOSITION WITH FC GAMMA IIIA RECEPTOR
EP2298805A3 (en) * 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
JP2007525187A (ja) 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
WO2005035741A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. ゲノムが改変された細胞
DE102004022895A1 (de) 2004-05-10 2005-12-08 Adam Opel Ag Schallabsorbierendes Verkleidungselement
JP2008505174A (ja) 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
EP1910542B1 (en) * 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES

Also Published As

Publication number Publication date
HRP20110503T1 (hr) 2011-08-31
DK2092069T3 (da) 2011-08-29
WO2008065543A3 (en) 2008-08-14
NO20092414L (no) 2009-08-21
CA2668932A1 (en) 2008-06-05
CY1112435T1 (el) 2015-12-09
US20120195851A1 (en) 2012-08-02
BRPI0719290A2 (pt) 2014-02-25
SI2092069T1 (sl) 2011-09-30
TN2009000184A1 (en) 2010-10-18
US20140030265A1 (en) 2014-01-30
ATE509106T1 (de) 2011-05-15
AU2007326985A1 (en) 2008-06-05
PT2092069E (pt) 2011-07-29
US8119770B2 (en) 2012-02-21
NI200900097A (es) 2010-01-26
MX2009005692A (es) 2009-10-12
EA018700B1 (ru) 2013-10-30
MA31143B1 (fr) 2010-02-01
AR063975A1 (es) 2009-03-04
IL198480A0 (en) 2011-08-01
EP2092069B1 (en) 2011-05-11
SV2009003272A (es) 2010-02-05
US20100061979A1 (en) 2010-03-11
PE20081250A1 (es) 2008-10-07
ECSP099361A (es) 2009-06-30
JP2010510801A (ja) 2010-04-08
PL2092069T3 (pl) 2011-10-31
WO2008065543A2 (en) 2008-06-05
TW200839012A (en) 2008-10-01
AU2007326985B2 (en) 2013-08-15
EA200970515A1 (ru) 2009-12-30
RS51911B (sr) 2012-02-29
CR10777A (es) 2009-07-23
AU2007326985C1 (en) 2014-02-20
MY145914A (en) 2012-05-15
EP2092069A2 (en) 2009-08-26
GT200900137A (es) 2011-09-02
CL2007003411A1 (es) 2008-07-04
US8481487B2 (en) 2013-07-09
KR20090102769A (ko) 2009-09-30
EP2092069B2 (en) 2013-12-18

Similar Documents

Publication Publication Date Title
CO6190564A2 (es) Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
BR112012005904A2 (pt) fibra, e, estrutura de fibra
MX2009010143A (es) Metodo para tratar una formacion fracturada.
DE602007009294D1 (de) Verstärkte pct-zusammensetzungen
WO2011014715A3 (en) Fluoropolymer compositions containing a polyol compound and methods of making them
BRPI0608413A2 (pt) métodos para fabricar um conjunto de agulha, e um conjunto introdutor de cateter
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
BR112012020596A8 (pt) substrato para a imobilização de substâncias funcionais e processo para preparar o mesmo.
ATE554769T1 (de) Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon
BRPI0807864A8 (pt) Complexo cristalino, processos de pasta fluida e de cisalhamento para a preparação do complexo cristalino e composição agrícola
WO2007137305A3 (en) A towel rail
ZA201002178B (en) 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors
WO2009024708A3 (fr) Face avant de véhicule automobile avec traverse au niveau des longerons principaux
WO2010104983A3 (en) Biological tissue connection and repair devices and methods of using same
BRPI0917841A2 (pt) método para tratar uma formação subterrânea penetrada por um furo de poço com componentes contendo ferro, e método para tratar uma formação subterrânea penetrada por um furo de poço tendo componentes contendo ferro
CR9934A (es) Composiciones de asilamiento libres de plomo mejoradas que contienen polimeros de metaloceno
BRPI0923316A2 (pt) método, e método de tratar uma formação penetrada por um poço.
BRPI1015447A8 (pt) Soluções pediátricas compreendendo um bloqueador beta
BRPI0719795A2 (pt) Junta soldada por feixe de elétrons excelente em resistência à fratura frágil
EP2284204A4 (en) COPOLYMER, METHOD FOR THE PRODUCTION THEREOF, AND WATER- AND OIL-REPELLING COMPOSITION THEREWITH
EP2718303A4 (en) NEW CYCLOPENTA [B-] FLUORENYL TRANSITION METAL COMPOUND, CATALYST COMPOSITION THEREOF, AND METHOD FOR PRODUCING AN ETHYLENE HOMOPOLYMER OR COPOLYMER FROM ETHYLENE AND alpha-OLEFIN THEREWITH
BRPI0707842B8 (pt) Ácido nucleico capaz de se ligar à mcp-1, seus usos, seu método de detecção, bem como composição farmacêutica, complexo, método para a triagem de um antagonista de quimiocina ou um agonista de quimiocina e kit para a detecção de uma quimiocina
BR112013003145A2 (pt) composição para controle de artrópodes nocivos e método para o controle de artrópodes nocivos
MX2009005679A (es) Fluoresceina sustancialmente pura.

Legal Events

Date Code Title Description
FC Application refused